Show simple item record

dc.contributor.authorWong, KH
dc.contributor.authorPanek, R
dc.contributor.authorDunlop, A
dc.contributor.authorMcquaid, D
dc.contributor.authorRiddell, A
dc.contributor.authorWelsh, LC
dc.contributor.authorMurray, I
dc.contributor.authorKoh, D-M
dc.contributor.authorLeach, MO
dc.contributor.authorBhide, SA
dc.contributor.authorNutting, CM
dc.contributor.authorOyen, WJ
dc.contributor.authorHarrington, KJ
dc.contributor.authorNewbold, KL
dc.date.accessioned2017-12-14T10:24:25Z
dc.date.issued2018-05
dc.identifier.citationEuropean journal of nuclear medicine and molecular imaging, 2018, 45 (5), pp. 759 - 767
dc.identifier.issn1619-7070
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/968
dc.identifier.eissn1619-7089en_US
dc.identifier.doi10.1007/s00259-017-3890-2en_US
dc.description.abstractObjective To assess the optimal timing and predictive value of early intra-treatment changes in multimodality functional and molecular imaging (FMI) parameters as biomarkers for clinical remission in patients receiving chemoradiation for head and neck squamous cell carcinoma (HNSCC).Methods Thirty-five patients with stage III-IVb (AJCC 7th edition) HNSCC prospectively underwent <sup>18</sup>F-FDG-PET/CT, and diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and susceptibility-weighted MRI at baseline, week 1 and week 2 of chemoradiation. Patients with evidence of persistent or recurrent disease during follow-up were classed as non-responders. Changes in FMI parameters at week 1 and week 2 were compared between responders and non-responders with the Mann-Whitney U test. The significance threshold was set at a p value of <0.05.Results There were 27 responders and 8 non-responders. Responders showed a greater reduction in PET-derived tumor total lesion glycolysis (TLG<sub>40%</sub>; p = 0.007) and maximum standardized uptake value (SUV<sub>max</sub>; p = 0.034) after week 1 than non-responders but these differences were absent by week 2. In contrast, it was not until week 2 that MRI-derived parameters were able to discriminate between the two groups: larger fractional increases in primary tumor apparent diffusion coefficient (ADC; p < 0.001), volume transfer constant (K<sup>trans</sup>; p = 0.012) and interstitial space volume fraction (V<sub>e</sub>; p = 0.047) were observed in responders versus non-responders. ADC was the most powerful predictor (∆ >17%, AUC 0.937).Conclusion Early intra-treatment changes in FDG-PET, DW and DCE MRI-derived parameters are predictive of ultimate response to chemoradiation in HNSCC. However, the optimal timing for assessment with FDG-PET parameters (week 1) differed from MRI parameters (week 2). This highlighted the importance of scanning time points for the design of FMI risk-stratified interventional studies.
dc.formatPrint-Electronic
dc.format.extent759 - 767
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHumans
dc.subjectCarcinoma, Squamous Cell
dc.subjectHead and Neck Neoplasms
dc.subjectFluorodeoxyglucose F18
dc.subjectPositron-Emission Tomography
dc.subjectDiffusion Magnetic Resonance Imaging
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectChemoradiotherapy
dc.subjectMultimodal Imaging
dc.subjectPositron Emission Tomography Computed Tomography
dc.titleChanges in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-11-13
rioxxterms.versionofrecord10.1007/s00259-017-3890-2
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-05en_US
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of nuclear medicine and molecular imaging
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume45en_US
pubs.embargo.termsNot known
icr.researchteamMagnetic Resonanceen_US
icr.researchteamTargeted Therapyen_US
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorWong, Keeen
dc.contributor.icrauthorMurray,en
dc.contributor.icrauthorKoh, Dow-Muen
dc.contributor.icrauthorOyen, Willemen
dc.contributor.icrauthorHarrington, Kevinen
dc.contributor.icrauthorLeach, Martinen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/